Concentrix is trading at $23.39 (5.4% up) as it extends a bounce following sharp post-earnings losses tied to lowered full-year revenue and EPS guidance.

  • Shares previously plunged between 17–20% following the June 29, 2026, second-quarter report and subsequent headlines regarding a securities probe.
  • The current upward move reflects a modest recovery as investors reassess the initial market overreaction within a mixed broader market environment.